SE537742C2 - Dextransulfat för cellmobilisering - Google Patents
Dextransulfat för cellmobilisering Download PDFInfo
- Publication number
- SE537742C2 SE537742C2 SE1350584A SE1350584A SE537742C2 SE 537742 C2 SE537742 C2 SE 537742C2 SE 1350584 A SE1350584 A SE 1350584A SE 1350584 A SE1350584 A SE 1350584A SE 537742 C2 SE537742 C2 SE 537742C2
- Authority
- SE
- Sweden
- Prior art keywords
- dextran sulfate
- cells
- mobilization
- csf
- subject
- Prior art date
Links
- 229960000633 dextran sulfate Drugs 0.000 title claims abstract description 203
- 210000000130 stem cell Anatomy 0.000 claims abstract description 122
- 210000004027 cell Anatomy 0.000 claims abstract description 117
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 69
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 51
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 48
- 239000011886 peripheral blood Substances 0.000 claims abstract description 48
- 230000001483 mobilizing effect Effects 0.000 claims abstract description 43
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 98
- 239000008280 blood Substances 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 36
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 8
- 230000001332 colony forming effect Effects 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 210000002960 bfu-e Anatomy 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract description 28
- 238000003306 harvesting Methods 0.000 abstract description 22
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 104
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 46
- 229960002169 plerixafor Drugs 0.000 description 42
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 36
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 229920002307 Dextran Polymers 0.000 description 29
- 229960002086 dextran Drugs 0.000 description 29
- 229910021653 sulphate ion Inorganic materials 0.000 description 28
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 21
- 210000001185 bone marrow Anatomy 0.000 description 21
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 20
- 238000002054 transplantation Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 17
- 238000002617 apheresis Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 230000002489 hematologic effect Effects 0.000 description 15
- 229940090044 injection Drugs 0.000 description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 9
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- -1 G-CSF Chemical class 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 108010029961 Filgrastim Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000001360 synchronised effect Effects 0.000 description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000011316 allogeneic transplantation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229940029345 neupogen Drugs 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011125 single therapy Methods 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 2
- 208000022120 Jeavons syndrome Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 229940074923 mozobil Drugs 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001550 time effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000037410 Complications after hematopoietic stem cell transplantation Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023249 Juvenile chronic myelomonocytic leukaemia Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000003525 myelopoietic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940092853 plerixafor injection Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000007015 preclinical effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350584A SE537742C2 (sv) | 2013-05-13 | 2013-05-13 | Dextransulfat för cellmobilisering |
| CA2912366A CA2912366C (en) | 2013-05-13 | 2014-05-12 | Dextran sulfate for use in mobilization of cells |
| PL14797927T PL2999478T3 (pl) | 2013-05-13 | 2014-05-12 | Siarczan dekstranu do stosowania do mobilizacji komórek |
| JP2016513900A JP6339668B2 (ja) | 2013-05-13 | 2014-05-12 | 細胞動員に使用するデキストラン硫酸 |
| EP14797927.2A EP2999478B1 (en) | 2013-05-13 | 2014-05-12 | Dextran sulfate for use in mobilization of cells |
| DK14797927.2T DK2999478T3 (da) | 2013-05-13 | 2014-05-12 | Dextransulfat til anvendelse ved mobilisering af celler |
| CN201480038833.5A CN105358159B (zh) | 2013-05-13 | 2014-05-12 | 用于细胞动员中的硫酸葡聚糖 |
| US14/890,636 US10258642B2 (en) | 2013-05-13 | 2014-05-12 | Dextran sulfate for use in mobilization of cells |
| PCT/SE2014/050576 WO2014185851A1 (en) | 2013-05-13 | 2014-05-12 | Dextran sulfate for use in mobilization of cells |
| BR112015028270-9A BR112015028270B1 (pt) | 2014-05-12 | Composição de mobilização de células para uso na mobilização de células progenitoras e/ou células tronco | |
| ES14797927T ES2780907T3 (es) | 2013-05-13 | 2014-05-12 | Sulfato de dextrano para su uso en la movilización de células |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350584A SE537742C2 (sv) | 2013-05-13 | 2013-05-13 | Dextransulfat för cellmobilisering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1350584A1 SE1350584A1 (sv) | 2014-11-14 |
| SE537742C2 true SE537742C2 (sv) | 2015-10-13 |
Family
ID=51898693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1350584A SE537742C2 (sv) | 2013-05-13 | 2013-05-13 | Dextransulfat för cellmobilisering |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10258642B2 (enExample) |
| EP (1) | EP2999478B1 (enExample) |
| JP (1) | JP6339668B2 (enExample) |
| CN (1) | CN105358159B (enExample) |
| CA (1) | CA2912366C (enExample) |
| DK (1) | DK2999478T3 (enExample) |
| ES (1) | ES2780907T3 (enExample) |
| PL (1) | PL2999478T3 (enExample) |
| SE (1) | SE537742C2 (enExample) |
| WO (1) | WO2014185851A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201408233D0 (en) | 2014-05-09 | 2014-06-25 | Austrianova Singapore Pte Ltd | Use of polyanionic composition |
| SE538503C2 (en) | 2014-11-11 | 2016-08-16 | Tx Medic Ab | New dextran sulfate |
| RU2623152C9 (ru) * | 2015-10-15 | 2022-02-17 | Акционерное общество "Федеральный научно-производственный центр "Алтай" | Композиция, обладающая гепатопротекторными и иммуностимулирующими свойствами |
| CN114127262A (zh) * | 2019-05-16 | 2022-03-01 | 香港中文大学 | 细胞外基质材料及其用途 |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3454560A (en) | 1966-03-01 | 1969-07-08 | Seikagaku Kogyo Co Ltd | Process for the production of chondroitin polysulfate |
| SE525461C3 (sv) | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| CN1589904A (zh) | 2003-09-01 | 2005-03-09 | 北京大学 | 造血干细胞动员剂制备治疗糖尿病药物的用途 |
-
2013
- 2013-05-13 SE SE1350584A patent/SE537742C2/sv unknown
-
2014
- 2014-05-12 EP EP14797927.2A patent/EP2999478B1/en active Active
- 2014-05-12 ES ES14797927T patent/ES2780907T3/es active Active
- 2014-05-12 DK DK14797927.2T patent/DK2999478T3/da active
- 2014-05-12 WO PCT/SE2014/050576 patent/WO2014185851A1/en not_active Ceased
- 2014-05-12 CN CN201480038833.5A patent/CN105358159B/zh active Active
- 2014-05-12 JP JP2016513900A patent/JP6339668B2/ja active Active
- 2014-05-12 CA CA2912366A patent/CA2912366C/en active Active
- 2014-05-12 US US14/890,636 patent/US10258642B2/en active Active
- 2014-05-12 PL PL14797927T patent/PL2999478T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10258642B2 (en) | 2019-04-16 |
| EP2999478A4 (en) | 2017-02-22 |
| CN105358159A (zh) | 2016-02-24 |
| US20160120897A1 (en) | 2016-05-05 |
| SE1350584A1 (sv) | 2014-11-14 |
| CA2912366C (en) | 2021-04-06 |
| BR112015028270A2 (pt) | 2017-07-25 |
| CA2912366A1 (en) | 2014-11-20 |
| JP6339668B2 (ja) | 2018-06-06 |
| DK2999478T3 (da) | 2020-04-14 |
| JP2016519143A (ja) | 2016-06-30 |
| CN105358159B (zh) | 2018-08-28 |
| EP2999478A1 (en) | 2016-03-30 |
| EP2999478B1 (en) | 2020-01-15 |
| PL2999478T3 (pl) | 2020-10-19 |
| WO2014185851A1 (en) | 2014-11-20 |
| ES2780907T3 (es) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200268850A1 (en) | Methods and compositions for mobilizing stem cells | |
| De Witte et al. | Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation | |
| Geissler et al. | Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates--synergism with recombinant human granulocyte/macrophage colony-stimulating factor | |
| SE537742C2 (sv) | Dextransulfat för cellmobilisering | |
| KR102784950B1 (ko) | 포유동물 세포의 보존액 | |
| Couban et al. | Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients | |
| CA2526244C (en) | Pharmaceutical combination of g-csf and plgf useful for blood stem cell mobilization | |
| JPH10510842A (ja) | 造血細胞の増加方法 | |
| Ataergin et al. | Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation | |
| EP2384760A1 (en) | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells | |
| Pospíšil et al. | Granulocyte colony‐stimulating factor and drugs elevating extracellular adenosine synergize to enhance haematopoietic reconstitution in irradiated mice | |
| US12162918B2 (en) | Periostin compounds for the treatment of haematological complications | |
| Amigo et al. | Factors that influence long-term hematopoietic function following autologous stem cell transplantation | |
| Vannucchi et al. | High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study | |
| BR112015028270B1 (pt) | Composição de mobilização de células para uso na mobilização de células progenitoras e/ou células tronco | |
| Rzepecki et al. | Sources of hematopoietic stem cells | |
| Mullen et al. | Clinical uses of recombinant haematopoietic growth factors in paediatrics | |
| Meehan et al. | Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients | |
| US8546353B2 (en) | Compounds and combinations | |
| Xu et al. | Hemangiopoietin supports animal survival and accelerates hematopoietic recovery of chemotherapy‐suppressed mice | |
| Fettah et al. | Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming | |
| RU2392947C1 (ru) | Способ получения клеточного материала для трансплантации при миелосупрессии | |
| Gulati et al. | Growth factors and hematopoietic recovery | |
| Briddell et al. | Recombinant rat stem cell factor synergizes with recombinant human |